Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
OncoSil Medical Ltd ( (AU:OSL) ) has shared an announcement.
OncoSil Medical Ltd has applied for quotation on the ASX of 4,723,060 additional ordinary fully paid shares, with an issue date of 9 February 2026. The new securities arise from transactions previously notified to the market, modestly expanding the company’s quoted capital base and potentially affecting liquidity and shareholder holdings once admitted to trading.
The application confirms compliance with ASX Listing Rules for quotation, indicating that the issuance follows standard market processes. While the announcement contains limited operational detail, it signals incremental capital structure activity that may support ongoing corporate or financing arrangements previously disclosed to investors.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$0.69 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical Ltd is an Australia-listed medical company focused on developing and commercialising oncology-related technologies. Its ordinary fully paid shares trade on the ASX under the ticker OSL, providing investors exposure to the healthcare and medical devices sector.
Average Trading Volume: 35,030
Technical Sentiment Signal: Sell
Current Market Cap: A$14.85M
For a thorough assessment of OSL stock, go to TipRanks’ Stock Analysis page.